Profile data is unavailable for this security.
About the company
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
- Revenue in USD (TTM)0.00
- Net income in USD-11.12m
- Incorporated2014
- Employees12.00
- LocationAzitra Inc21 Business Park Drive, Suite 6BRANFORD 06405United StatesUSA
- Phone+1 (203) 489-0183
- Fax+1 (302) 655-5049
- Websitehttps://azitrainc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InMed Pharmaceuticals Inc | 4.51m | -7.66m | 2.39m | 13.00 | -- | 0.2398 | -- | 0.5312 | -4.08 | -4.08 | 1.72 | 3.42 | 0.4577 | 3.09 | 20.23 | -- | -77.84 | -87.37 | -93.34 | -107.49 | 29.73 | -- | -170.07 | -356.16 | 5.30 | -- | 0.00 | -- | 7.50 | -- | -6.34 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 2.42m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -12.88m | 2.42m | 7.00 | -- | -- | -- | -- | -15.97 | -15.97 | 0.00 | -0.6301 | 0.00 | -- | -- | 0.00 | -343.49 | -- | -1,530.48 | -- | -- | -- | -- | -- | -- | -44.72 | -- | -- | -- | -- | -31.07 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -10.71m | 2.55m | 9.00 | -- | 0.8419 | -- | -- | -25.86 | -25.86 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -507.78 | -- | -3,614.50 | -- | -- | -- | -- | -- | -- | -- | 0.2305 | -- | -- | -- | -38.71 | -- | -- | -- |
| Psyence Biomedical Ltd | -100.00bn | -100.00bn | 2.62m | 12.00 | -- | 0.0103 | -- | -- | -- | -- | -- | 247.64 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 101.98 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -376.18k | 2.62m | 0.00 | -- | 10.44 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0006 | 0.00 | -- | -- | -- | -78.62 | -530.88 | -117.20 | -607.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.34 | -- | 18.34 | -- |
| Azitra Inc | 0.00 | -11.12m | 2.66m | 12.00 | -- | 0.4043 | -- | -- | -5.49 | -5.49 | 0.00 | 0.4066 | 0.00 | -- | -- | 0.00 | -157.91 | -- | -203.88 | -- | -- | -- | -- | -- | -- | -- | 0.1197 | -- | -98.91 | -- | 29.05 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -8.05m | 2.74m | 5.00 | -- | 0.5228 | -- | -- | -23.22 | -23.22 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -130.16 | -205.76 | -155.01 | -274.10 | -- | -- | -- | -- | -- | -27.38 | 0.00 | -- | -- | -- | -88.48 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.85m | 2.74m | 8.00 | -- | 0.2452 | -- | -- | -28.37 | -28.37 | 0.00 | 4.69 | 0.00 | -- | -- | 0.00 | -150.49 | -136.32 | -203.36 | -201.56 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -57.64 | -- | -- | -- |
| Vaccinex Inc | 601.00k | -18.63m | 2.76m | 23.00 | -- | -- | -- | 4.59 | -9.91 | -9.91 | 0.2864 | -0.9295 | 0.193 | -- | 0.6682 | 26,130.44 | -598.49 | -299.11 | -- | -- | -- | -- | -3,100.50 | -3,700.14 | -- | -149.88 | -- | -- | 5.44 | 2.82 | 7.98 | -- | -22.36 | -- |
| Propanc Biopharma Inc | 0.00 | -67.00m | 2.89m | 1.00 | -- | 0.2345 | -- | -- | -13.54 | -13.54 | 0.00 | 0.851 | 0.00 | -- | -- | 0.00 | -869.88 | -- | -1,782.95 | -- | -- | -- | -- | -- | -- | -74.43 | 0.0492 | -- | -- | -- | -2,826.43 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -11.25m | 3.13m | 5.00 | -- | 0.1421 | -- | -- | -94.63 | -94.63 | 0.00 | 15.83 | 0.00 | -- | -- | 0.00 | -212.68 | -146.94 | -262.78 | -198.90 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.16 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Alumni Capital Management LLCas of 02 Jan 2026 | 1.13m | 10.55% |
| Geode Capital Management LLCas of 31 Dec 2025 | 77.61k | 0.72% |
| DRW Securities LLCas of 31 Dec 2025 | 61.82k | 0.58% |
| XTX Markets LLCas of 31 Dec 2025 | 28.23k | 0.26% |
| Jane Street Capital LLCas of 31 Dec 2025 | 22.25k | 0.21% |
| Two Sigma Investments LPas of 31 Dec 2025 | 20.29k | 0.19% |
| Sassicaia Capital Advisers LLCas of 31 Dec 2025 | 14.06k | 0.13% |
| UBS Securities LLCas of 31 Dec 2025 | 998.00 | 0.01% |
| Tower Research Capital LLCas of 31 Dec 2025 | 99.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 72.00 | 0.00% |
